GILD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.65B

+1.09%

1.884

-0.85%

7.04B

+5.58%

2.027

+12.02%

7.49B

+5.78%

2.186

+8.77%

Estimates Revision

The market is revising Upward the revenue expectations for Gilead Sciences, Inc. (GILD) for FY2025, with the revenue forecasts being adjusted by 1.45% over the past three months. During the same period, the stock price has changed by 9.03%.

Revenue Estimates for FY2025

Revise Upward

+1.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.07%

In Past 3 Month

Stock Price

Go Up

+9.03%

In Past 3 Month

19 Analyst Rating

Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 135.00 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

3 Hold

0 Sell

Strong Buy

Current: 122.700

Low

105.00

Averages

135.00

High

150.00

Current: 122.700

Low

105.00

Averages

135.00

High

150.00

Morgan Stanley

Overweight

maintain

$147 -> $151

2025-12-12

New

Reason

Morgan Stanley

Price Target

$147 -> $151

2025-12-12

New

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Gilead to $151 from $147 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

HSBC

Hold

maintain

$110 -> $133

2025-12-10

New

Reason

HSBC

Price Target

$110 -> $133

2025-12-10

New

maintain

Hold

Reason

HSBC raised the firm's price target on Gilead to $133 from $110 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

Needham

Buy

maintain

$14

2025-12-08

Reason

Needham

Price Target

$14

2025-12-08

maintain

Buy

Reason

Needham reiterated a Buy rating and $14 price target on Vir Biotechnology (VIR), saying that Mirum's (MIRM) announced takeover of Bluejay Therapeutics is a positive readthrough to Vir. The firm believes this given its view that Vir's elebsiran/tobevibart profile is better than Bluejay and Gilead (GILD); the deal signals very high interest in the Hepatitis Delta Virus commercial opportunity, and; the deal size is quite favorable for a potentially third-to-market asset. The firm anticipates Vir to trade up Monday on the news and believes the company's HDV program is underappreciated by investors and not adequately reflected in the stock at current levels.

Truist

Gregory Renza

Buy

downgrade

$145 -> $140

2025-11-24

Reason

Truist

Gregory Renza

Price Target

$145 -> $140

2025-11-24

downgrade

Buy

Reason

Truist analyst Gregory Renza assumed coverage of Gilead with a Buy rating with a price target of $140, down from $145. The firm is positive on the continued strength for the company's HIV franchise, supported by Biktarvy's patent settlement and positive momentum across next-generation programs,most notably Yeztugo's PrEP launch and Bic/Len's positive phase 3 readout, pointing to a healthy outlook into the next-decade, the analyst tells investors in a research note. Truist adds that it also views the oncology franchise as a key growth pillar led by Trodelvy and anito-cel, further noting that Livdelzi's launch in PBC - Primary Biliary Cholangitis - is off to a strong start.

BMO Capital

Outperform

maintain

$135

2025-11-24

Reason

BMO Capital

Price Target

$135

2025-11-24

maintain

Outperform

Reason

BMO Capital says Phase 1 data from three patients in Kelonia Therapeutics' inMMyCAR study "look interesting," with all patients reaching MRD negativity by month one, but adds that the extremely small sample size and limited amount of patient follow-up "muddies comparisons" to Gilead (GILD) and Arcellx's (ACLX) anito-cel program. The tolerability profile of Kelonia's KLN-1010 "looks relatively clean," but the small sample size and the limited amount of patient follow-up "leave significant questions," adds the analyst, who keeps an Outperform rating and $135 price target on Gilead shares.

Mizuho

Outperform

maintain

$131 -> $140

2025-11-20

Reason

Mizuho

Price Target

$131 -> $140

2025-11-20

maintain

Outperform

Reason

Mizuho raised the firm's price target on Gilead to $140 from $131 and keeps an Outperform rating on the shares. The firm raised its price target primarily due to: Biktarvy's loss of exclusivity in the U.S. now expected to be 2036 instead of 2033 post generic lititgation settlements; the total addressable market for PrEP could be much larger than currently appreciated, and; the firm now models roughly 5% growth for Gilead's HIV business overall, from roughly 3% prior.

Valuation Metrics

The current forward P/E ratio for Gilead Sciences Inc (GILD.O) is 14.31, compared to its 5-year average forward P/E of 11.55. For a more detailed relative valuation and DCF analysis to assess Gilead Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

11.55

Current PE

14.31

Overvalued PE

14.17

Undervalued PE

8.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

8.57

Current EV/EBITDA

9.69

Overvalued EV/EBITDA

9.87

Undervalued EV/EBITDA

7.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.69

Current PS

4.99

Overvalued PS

4.29

Undervalued PS

3.10

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 606.95% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 606.95% over the last month.

Sold

Bought

GILD News & Events

Events Timeline

No data

News

9.0

12-12Benzinga

Arcus Overhauls Cancer Development Strategy After Trial Setback, Focuses on Kidney Medication

9.0

12-12Newsfilter

Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy

9.0

12-12NASDAQ.COM

Arcus Biosciences and Gilead Halt Phase 3 STAR-221 Cancer Study Due to Lack of Efficacy

People Also Watch

Frequently Asked Questions

What is Gilead Sciences Inc (GILD) stock price today?

The current price of GILD is 122.7 USD — it has increased 1.91 % in the last trading day.

What is Gilead Sciences Inc (GILD)'s business?

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

What is the price predicton of GILD Stock?

What is Gilead Sciences Inc (GILD)'s revenue for the last quarter?

Gilead Sciences Inc revenue for the last quarter amounts to 7.77B USD, increased 2.97 % YoY.

What is Gilead Sciences Inc (GILD)'s earnings per share (EPS) for the last quarter?

Gilead Sciences Inc. EPS for the last quarter amounts to 2.43 USD, increased 143.00 % YoY.

What changes have occurred in the market's expectations for Gilead Sciences Inc (GILD)'s fundamentals?

How many employees does Gilead Sciences Inc (GILD). have?

Gilead Sciences Inc (GILD) has 17600 emplpoyees as of December 15 2025.

What is Gilead Sciences Inc (GILD) market cap?

Today GILD has the market capitalization of 149.38B USD.